Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
about
Prostaglandin E2 signals through PTGER2 to regulate sclerostin expressionCYR61 regulates BMP-2-dependent osteoblast differentiation through the {alpha}v{beta}3 integrin/integrin-linked kinase/ERK pathwayBone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator functionSOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitorControl of the SOST bone enhancer by PTH using MEF2 transcription factorsPolymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites.Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathwaysEffects of PTH on osteocyte functionSclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and ChallengesFrom disease to treatment: from rare skeletal disorders to treatments for osteoporosisRoles of the kidney in the formation, remodeling and repair of boneImpact of inflammation on the osteoblast in rheumatic diseasesFunctions of the osteocyte network in the regulation of bone massEndocrine crosstalk between muscle and boneThe osteocyte as a therapeutic target in the treatment of osteoporosisBone as an endocrine organModulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal OsteoporosisThe DAN family: modulators of TGF-β signaling and beyondControl of bone mass and remodeling by PTH receptor signaling in osteocytesCharacterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATIONFluorescence-based force/tension sensors: a novel tool to visualize mechanical forces in structural proteins in live cellsBone Cells Dynamics during Peri-Implantitis: a Theoretical AnalysisNoggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complexWNT signaling in bone homeostasis and disease: from human mutations to treatmentsSingle-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibodyRegulation of Wnt/β-catenin signaling within and from osteocytesSclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteinsFrom estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosisGenetic evidence that SOST inhibits WNT signaling in the limbMutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibitionBinge alcohol-induced bone damage is accompanied by differential expression of bone remodeling-related genes in rat vertebral boneParathyroid hormone signaling through low-density lipoprotein-related protein 6Single-pulsed electromagnetic field therapy increases osteogenic differentiation through Wnt signaling pathway and sclerostin downregulation.A novel underuse model shows that inactivity but not ovariectomy determines the deteriorated material properties and geometry of cortical bone in the tibia of adult rats.Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort.Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathwayIncreased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR CohortWise regulates bone deposition through genetic interactions with Lrp5Nuclear alpha NAC influences bone matrix mineralization and osteoblast maturation in vivo
P2860
Q21560844-23CE4FB4-9C35-4D80-A046-7E00253FED82Q24293652-FF09C12A-7D7E-4BDF-A7BF-38987F7392BFQ24299076-0322709B-13CC-4288-8BA5-F2378D6C055EQ24303393-BA702E03-3647-4B94-8662-094991592075Q24337339-D929810C-7FA2-4010-8F36-C64FE3878639Q24534143-A0FBCB0A-16C9-4213-AC62-6B88EDF18408Q24621990-25E91A98-B371-40DE-BD9E-E13B0ECE7D50Q24631082-6875524E-1A45-4556-996E-0F9D96B8152FQ26744599-CCB830FA-99E0-4411-B14B-FE07DAB45329Q26764854-F9AA5ECB-F3C2-48C5-B5DB-F6C035985788Q26768186-2EFBB36A-BC12-43FA-99C2-096886CEA3BCQ26829246-7FCA36AB-9119-4518-908F-A44BCA1FB870Q27002647-433B1C58-8125-4A1D-B199-228FFB9DA373Q27008987-55CFE6A1-DA35-448F-BA72-5123508831D4Q27009129-916F164E-F1BA-406C-A71F-C97A72557153Q27010173-32382E53-127F-47CA-A086-AB06140CF524Q27022580-1754594B-C275-4CAD-B5AA-D5526E299D26Q27025762-52F569F6-2374-4F56-B308-937F1D8E0108Q27300741-430B8D7E-3FFC-4E84-9495-DC213720C10FQ27653715-56F998AA-FE84-4775-B5FE-5117FC22B9AAQ27693233-651D703F-5D08-4A44-8ECA-CE234F9A2EDEQ28066397-05D27D08-44B2-4D65-B589-F73ADC7053E1Q28267086-840CC84D-FC9F-4BC1-8279-24EB35826FAFQ28285090-0957F664-56A9-497B-A99D-4604D95415EFQ28286616-D55E0A57-10F4-49A8-B80D-378D3C03FC7CQ28286814-4877E940-5650-4436-982C-74164F36B67DQ28293474-8A4C7A83-9C13-4A3A-996B-F867B5DBBA84Q28385120-BB926166-F2E0-457B-BDF2-FADE4A00F99EQ28509512-0F309079-63EE-4CC3-A53B-250726D84C0DQ28535490-B5295027-8EC6-48FA-AF42-FB8A4890570CQ28566615-00958721-E816-4AD7-B97C-0BB506BBEEECQ28567926-21F810A5-40E9-4F99-AC73-F79B3E5777F3Q30278695-C56E3CC0-E77A-43BE-AFE2-0924BD766B06Q30502342-E6B438C4-0FC1-4868-83BE-C3651546B0D0Q30914003-B265A46B-C53F-40CE-9637-B50B63483E89Q30990351-194DB076-0520-43C1-8A80-1BA3AEC5AAC0Q31032805-C6F48CB7-D276-45FF-95BA-E18CB78FB390Q31038073-C2366BEC-DFC2-4A8F-AACE-29DDBDE35017Q33553692-8B8649D1-E2D2-44E0-A228-0090EAED09C1Q33558145-FD3B98F4-22C7-4B1F-AE59-0A295CA28884
P2860
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@ast
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@en
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@en-gb
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@nl
type
label
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@ast
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@en
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@en-gb
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@nl
prefLabel
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@ast
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@en
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@en-gb
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@nl
P2093
P2860
P3181
P356
P1433
P1476
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
@en
P2093
Brian R Kovacevich
Changpu Yu
David G Winkler
Diana Shpektor
James C Geoghegan
John A Latham
John E Skonier
Karen Staehling-Hampton
Mark Appleby
Mary E Brunkow
P2860
P304
P3181
P356
10.1093/EMBOJ/CDG599
P407
P577
2003-12-01T00:00:00Z